The program will feature a keynote address by Leroy Hood, MD, PhD, an internationally renowned scientist and pioneer in personalized medicine, who founded the Institute of Systems Biology in Seattle.

Panel Discussion Featuring

David Satcher, MD, PhD
Director of the Satcher Health Leadership Institute at Morehouse School of Medicine and the 16th Surgeon General of the United States.

Kenneth L. Brigham, MD
Associate Vice President and Director of the Predictive Health Institute at Emory University and Georgia Institute of Technology.

Valerie Montgomery Rice, MD
Dean and Executive Vice President of Morehouse School of Medicine.

Elizabeth Ofili, MD, MPH
Associate Dean and Director of the Clinical Research Center at Morehouse School of Medicine, national principal investigator of the WARFARIN study, a first of its kind personalized medicine study approved by the Centers for Medicare and Medicaid Services.

Roger Simon, MD
Director of Translational Programs in Stroke and Professor of Neurology and Neurobiology at Morehouse School of Medicine.

David Stephens, MD
VP of Research at Emory University’s Woodruff Health Sciences Center.

Fred Sanfilippo, MD, PhD
Director of the Emory University and Georgia Institute of Technology Healthcare Innovation Program

Keynote Address Welcome

John Maupin, DDS, MBA
President, Morehouse School of Medicine

Proclamation & Opening Remarks

Governor Nathan Deal will proclaim Sept 1, 2011, as Personalized Medicine Awareness Day in Georgia and kick off a half-day program to mark the occasion at Morehouse School of Medicine.

September 1, 2011
Event: 1pm – 4pm

Louis W. Sullivan
National Center for Primary Care
Morehouse School of Medicine
720 Westview Dr SW, Atlanta, GA

Cocktail Reception: 4-5pm

Louis W. Sullivan
National Center for Primary Care
E. Ginger Sullivan Atrium

The program is being organized by Morehouse School of Medicine, Emory University and Georgia Institute of Technology, all of which participate in an NIH-funded consortium called the Atlanta Clinical and Translational Science Institute (ACTSI). Georgia Bio is a partner of ACTSI and is participating in the program, along with Iverson Genetic Diagnostics. Iverson has a collaboration with Morehouse and ACTSI in a clinical research study of a new technology that will make the practice of personalized medicine possible. Georgia’s healthcare institutions are leading sites for the study.